Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | recruiting | Phase 1 / Phase 2 | 151 | TakedaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07437963 | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse | not yet recruiting | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07529717 |
| First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer(CRIUS-1) |
| recruiting |
| Phase 1 / Phase 2 |
| 42 |
| AstraZenecaINDUSTRY |
| 3 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT07556822 | Phase I Study of HRS-3005 in B-cell Malignancies | recruiting | Phase 1 | 190 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07676890 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVIV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07724106 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVSV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07796620 | Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | not yet recruiting | Phase 1 / Phase 2 | 40 | Peking University People's HospitalOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07805369 | A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer | not yet recruiting | Phase 1 | 60 | DEM BioPharma, Inc.INDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07811076 | Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer(SG-RCT) | not yet recruiting | Phase 1 / Phase 2 | 140 | Xuelei Ma MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01044069 | Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | active not recruiting | Phase 1 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01746238 | Bevacizumab/Doxorubicin/Radiation for Sarcoma | active not recruiting | Phase 1 | 14 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03006172 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | active not recruiting | Phase 1 | 200 | Genentech, Inc.INDUSTRY | 5 | Sep 8, 2026 | clinicaltrials |
| NCT03631017 | Imaging With a PET Agent for Detection of Cancers of the Head and Neck | active not recruiting | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | recruiting | Phase 1 | 411 | Inhibrx Biosciences, IncINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT03939897 | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04577014 | Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 98 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 332 | Hoffmann-La RocheINDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT05307705 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors(PIKASSO-01) | recruiting | Phase 1 | 260 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT05800665 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Genentech, Inc.INDUSTRY | 7 | Sep 8, 2026 | clinicaltrials |
| NCT06539338 | A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment(INVISE) | active not recruiting | Phase 1 | 10 | Kite, A Gilead CompanyINDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
| NCT06561685 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 340 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies(Soundtrack-E) | recruiting | Phase 1 / Phase 2 | 408 | AstraZenecaINDUSTRY | 13 | Sep 8, 2026 | clinicaltrials |
| NCT06624085 | A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 50 | Hoffmann-La RocheINDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
| NCT06861452 | Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma(SNIPER) | recruiting | Phase 1 / Phase 2 | 9 | EIR Biotherapies s.r.l.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06902376 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer(NEO-COMBATXL) | recruiting | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07100106 | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer(MoonROSE) | recruiting | Phase 1 / Phase 2 | 285 | Genentech, Inc.INDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT07367529 | A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection | recruiting | Phase 1 / Phase 2 | 465 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07444632 | Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07563829 | NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies | recruiting | Phase 1 | 81 | NextPoint Therapeutics, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07718243 | Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC(BLAZE) | recruiting | Phase 1 / Phase 2 | 62 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07734116 | A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. | recruiting | Phase 1 / Phase 2 | 50 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07735377 | A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer | recruiting | Phase 1 | 118 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806058 | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806175 | A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 486 | Rongchang Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing Anjianxi Bio-Medical Technology Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807800 | A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) | not yet recruiting | Phase 1 / Phase 2 | 88 | D. E. Shaw Research, LLCINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01695941 | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01711554 | Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma | active not recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 2 | Sep 4, 2026 | clinicaltrials |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | active not recruiting | Phase 1 | 159 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03386513 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | active not recruiting | Phase 1 / Phase 2 | 179 | AbbVieINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT03608631 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | recruiting | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03911388 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04391049 | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | active not recruiting | Phase 1 | 16 | NRG OncologyOTHER | 1 | Sep 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 9, 2026source: clinicaltrials